Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

GSK Buys Nanjing MeiRui Pharma for $70 Million

publication date: Dec 7, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
GlaxoSmithKline will pay $70 million to purchase Nanjiing MeiRui Pharma, a company with natural products that treat urology and allergy conditions. In recent years, GSK has been very active in making deals that increase its presence in emerging markets. With the acquisition, GSK gains a company that has established relationships with urologists, which it will use to market Avodart, its own treatment for benign prostatic hyperplasia (enlarged prostate). More details....

Stock Symbol: (NYSE: GSK)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
ChinaBio® Events
Shanghai, China
April 14-15, 2015

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors